CRISPR zaps HPV in cervical lesions: first human test begins
NCT ID NCT07170254
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up by 36 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CRISPR/Cas9 gene therapy (BD114VLP or BD114) injected directly into cervical lesions
- What this could lead to
- If successful, this could point toward a one-time gene-editing treatment to clear HPV-16-related high-grade cervical lesions without surgery.
- What could go wrong
- This is a very early, small trial with only 12 participants, so results may not apply broadly. Gene editing carries unknown long-term risks, and the therapy may not effectively clear lesions or HPV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (CIN3) ASSOCIATED WITH HPV-16 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, 200090, China